Intracranial Meningioma Risks Are Increased When Depo-Provera Was Used for More Than One Year
(Posted by Tom Lamb at Drug Injury Watch)
A medical journal article published in March 2024 reported that Depo-Provera (medroxyprogesterone acetate) increased the risk of intracranial meningioma by 5.6 times if Depo-Provera was used as birth control for longer than a year.
The contraceptive injection Depo-Provera being linked to brain tumors in some women is a still emerging drug safety issue that has recently resulted in some drug injury lawsuits seeking legal compensation being filed against the responsible pharmaceutical companies.
Intracranial meningiomas are mostly non-cancerous or non-malignant tumors that grow in layers of tissue covering the brain and spinal cord. However, cancerous or malignant meningiomas account for 40% of cancers in the central nervous system. Both of these forms of intracranial meningioma are potentially serious medical conditions.
__________________________________________________________________
Depo-Provera Contraceptive Injection
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
This March 2024 BMJ article, "Use of progestogens and the risk of intracranial meningioma: national case-control study", provides these details about the increased risk of intracranial meningioma associated with the use of Depo-Provera, a widely used injectable birth control or contraceptive product in the US and around the world.
- "Meningiomas account for 40% of primary tumours of the central nervous system. The incidence of meningioma in the United States is 9.5 per 100 000 person years. Meningiomas are mostly slow growing, histologically benign tumours but can nevertheless compress adjacent brain tissue and thus patients may require surgical decompression. The incidence of meningiomas increases with age, rising sharply after the age of 65 years. Conversely, meningiomas are rare before the age of 35." [Footnotes omitted.]
- An excess risk of meningioma (odds ratio 5.55 (2.27 to 13.56)) was associated with the use of Depo-Provera (medroxyprogesterone acetate).
- Meningiomas before age 45 years were rare (n=3/9) in cases of exposure to Depo-Provera (medroxyprogesterone acetate).
If you are interested in reviewing some general medical information about meningioma, we direct you to the Mayo Clinic's "Symptoms & causes" and "Diagnosis & treatment" web pages.
We point out that the current drug label information for Depo-Provera Contraceptive Injection (Depo-Provera CI), version "Revised: 7/2024", does not include any warning about an increased risk of intracranial meningioma.
For this reason, i.e., failure to warn, we are investigating cases of the contraceptive injection Depo-Provera being linked to brain tumors in some women as possible drug injury lawsuits against the responsible pharmaceutical companies.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects
Drug Injury Case Evaluation - Free. Confidential. No Obligation.